Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis

Abstract Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.

Saved in:
Bibliographic Details
Main Authors: Bonfiglioli,Karina Rossi, Mota,Licia Maria Henrique da, Ribeiro,Ana Cristina de Medeiros, Kakehasi,Adriana Maria, Laurindo,Ieda Maria Magalhães, Giorgi,Rina Dalva Neubarth, Duarte,Angela Luzia Branco Pinto, Reis,Ana Paula Monteiro Gomides, Souza,Mariana Peixoto Guimarães Ubirajara e Silva de, Brenol,Claiton Viegas, Pinheiro,Geraldo da Rocha Castelar, Albuquerque,Cleandro Pires de, Castro,Charlles Heldan de Moura, Pinto,Gustavo Luiz Behrens, Verztman,Jose Fernando, Muniz,Luciana Feitosa, Bertolo,Manoel Barros, Pinto,Maria Raquel da Costa, Louzada Júnior,Paulo, Cruz,Vitor Alves, Pereira,Ivanio Alves, Freitas,Max Vitor Carioca de, Cruz,Bóris Afonso, Paiva,Eduardo, Monticielo,Odirlei, Provenza,José Roberto, Xavier,Ricardo Machado
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Reumatologia 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2523-31062021000100303
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Rheumatoid arthritis (RA) is a chronic and autoimmune systemic inflammatory disease that can cause irreversible joint deformities, with increased morbidity and mortality and a significant impact on the quality of life of the affected individual. The main objective of RA treatment is to achieve sustained clinical remission or low disease activity. However, up to 40% of patients do not respond to available treatments, including bDMARDs. New therapeutic targets for RA are emerging, such as Janus kinases (JAKs). These are essential for intracellular signaling (via JAK-STAT) in response to many cytokines involved in RA immunopathogenesis. JAK inhibitors (JAKi) have established themselves as a highly effective treatment, gaining increasing space in the therapeutic arsenal for the treatment of RA. The current recommendations aim to present a review of the main aspects related to the efficacy and safety of JAKis in RA patients, and to update the recommendations and treatment algorithm proposed by the Brazilian Society of Rheumatology in 2017.

Similar Items